Endometrial cancer ranks sixth in the structure of cancer incidence in women, being an important public health problem in almost all countries. In the structure of the incidence of malignant neoplasms in women, endometrial cancer occupies the sixth place, accounting for 5.3% of all tumors. Survival of patients with endometrial cancer with metastases is dependent on the stage, depth of tumor invasion and treated with the use of neoadjuvant chemotherapy and subsequent radical surgery: so indicators five-year relapse-free and overall survival was 79.6 percent and 87.5%, respectively in patients with endometrial cancer stages IB2 – IIIB, which is about 20% higher than among patients who underwent only radiation combined terapiya.